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A B S T R A C T
Agonists of the nuclear receptor PPARg are therapeutically used to combat hyperglycaemia associated
with the metabolic syndrome and type 2 diabetes. In spite of being effective in normalization of blood
glucose levels, the currently used PPARg agonists from the thiazolidinedione type have serious side
effects, making the discovery of novel ligands highly relevant.
Natural products have proven historically to be a promising pool of structures for drug discovery, and
a signiﬁcant research effort has recently been undertaken to explore the PPARg-activating potential of a
wide range of natural products originating from traditionally used medicinal plants or dietary sources.
The majority of identiﬁed compounds are selective PPARg modulators (SPPARMs), transactivating the
expression of PPARg-dependent reporter genes as partial agonists. Those natural PPARg ligands have
different binding modes to the receptor in comparison to the full thiazolidinedione agonists, and on
some occasions activate in addition PPARa (e.g. genistein, biochanin A, sargaquinoic acid,
sargahydroquinoic acid, resveratrol, amorphastilbol) or the PPARg-dimer partner retinoid X receptor
(RXR; e.g. the neolignans magnolol and honokiol). A number of in vivo studies suggest that some of the
natural product activators of PPARg (e.g. honokiol, amorfrutin 1, amorfrutin B, amorphastilbol) improve
metabolic parameters in diabetic animal models, partly with reduced side effects in comparison to full
thiazolidinedione agonists. The bioactivity pattern as well as the dietary use of several of the identiﬁed
active compounds and plant extracts warrants future research regarding their therapeutic potential and
the possibility to modulate PPARg activation by dietary interventions or food supplements.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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The metabolic syndrome is currently a major worldwide
epidemic. It strongly associates with obesity, insulin resistance,
type 2 diabetes, and cardiovascular diseases, which are major
pathologies contributing to mortality and morbidity worldwide. At
present the metabolic syndrome is already affecting more than a
quarter of the world’s adult population. Its prevalence is further
growing in both adults and children due to a life style characterized
by high calorie nutrition combined with low physical activity [1,2].
The metabolic syndrome represents by deﬁnition a disorder
related to imbalance of energy utilization and storage. Its features
include abdominal obesity, hypertension, dyslipidemia (increased
blood serum triglycerides; low high-density lipoprotein (HDL) and
high low-density lipoprotein (LDL) cholesterol levels), insulin
resistance with elevated fasting blood glucose, and glucose
intolerance as well as establishment of pro-thrombotic and pro-
inﬂammatory states [3]. People affected by the metabolic
syndrome have a greater risk of developing cardiovascular diseases
and type 2 diabetes. Moreover, recent research indicates that
metabolic syndrome associated obesity causes chronic low-grade
Fig. 1. PPARg transcriptional activation. (1) Binding of activating ligands to PPARg
and to its dimer partner RXR; (2) following the ligand binding there are
conformational changes of the receptors, resulting in re-arrangement of the
transcriptional complex and changes in the associated transcriptional cofactors; (3)
resulting from this reorganization, the transcriptional complex is activated and
initiates changes in the expression of the regulated PPARg target genes.local tissue inﬂammation and increased susceptibility to other
disease conditions such as fatty liver, sleep disturbances,
cholesterol gallstones, polycystic ovary syndrome, asthma, and
some types of cancer [3,4].
The two main approaches in metabolic syndrome management
are in the ﬁrst place life style modiﬁcations that aim at restoring
energy balance by reduced calorie intake and increased energy
expenditure by physical activity, and on second place pharmaceu-
tical interventions [1,3]. Employed drugs target different relevant
aspects of the metabolic syndrome such as body weight and fat
distribution, insulin resistance, hypertension, dyslipidemia, hy-
perglycemia, or the established prothrombotic and proinﬂamma-
tory state [3]. For the treatment of patients suffering from type 2
diabetes, aside from life-style alterations, insulin and insulin
analogs were ﬁrst applied [5]. Later a number of oral anti-
hyperglycemic pharmaceuticals were developed and successfully
used [6] including sulfonylureas (increasing insulin secretion) [7],
biguanides (insulin sensitizers; e.g. metformin), alpha-glucosidase
inhibitors (slowing the digestion of starch in the small intestine),
meglitinides (increasing insulin secretion), dipeptidylpeptidase 4
(DPP-4) inhibitors (increasing insulin secretion) [6], as well as
thiazolidinediones (agonists of PPARg). Recent research strategies
also explore targeting the nuclear factor-kappaB (NF-kB) pathway
[8], mitogen-activated protein kinases (MAPK) signaling [9], fatty
acid-binding proteins [10], as well as other targets involved in fatty
acid metabolism [11,12]. PPARg, the molecular target of the
thiazolidinediones, is particularly involved in the regulation of
insulin sensitivity, inﬂammation, fatty acid storage, and glucose
metabolism, and therefore represents an especially interesting
pharmacological target which is able to simultaneously modulate
several of the underlying pathologies of the metabolic syndrome
[13,14].
2. PPARg and the metabolic regulation
PPARs belong to a subfamily of the nuclear receptor superfamily
of ligand-inducible transcription factors [15]. To date, three PPAR
isotypes encoded by separate genes have been identiﬁed, PPARa
[16], PPARb/d, and PPARg [17].
PPARs mainly control the expression of gene networks involved
in adipogenesis, lipid metabolism, inﬂammation, and the mainte-
nance of metabolic homeostasis. As they can be activated by
dietary fatty acids and their metabolites, they act as lipid sensors
that, upon activation, are able to markedly redirect metabolism
[18–20]. The gene transcription process is identical in all threePPAR subtypes (Fig. 1): After ligand binding, PPARs form
heterodimers with another ligand-activated nuclear receptor,
the retinoid X receptor (RXR). The PPAR-RXR heterodimer binds
to peroxisome proliferator response elements (PPREs) in the
promoter region of the respective target genes. The transcription
process is then initiated upon recruitment of different transcrip-
tional cofactors [21–24] (Fig. 1).
The three PPAR isotypes possess a distinct tissue distribution
and have different functions in the regulation of energy metabo-
lism. PPARa is highly expressed in muscles, liver, heart, and
kidney, and mainly regulates genes involved in the metabolism of
lipids and lipoproteins [20,25–27]. PPARb/d is abundantly
expressed throughout the body but at low levels in the liver. It
has emerged as an important regulator of lipid metabolism and
energy balance primarily in adipose tissue, skeletal muscle, and the
heart [25,28,29]. The PPARg protein exists in two isoforms that are
expressed from the same gene by utilizing distinct promoters and
50exons. PPARg2 differs from PPARg1 by the presence of an
additional stretch of 30 amino acid residues in the ligand-
independent domain at the N-terminal end resulting in a higher
transcriptional activity compared to PPARg1 [30–32]. The two
PPARg isoforms also show a distinct expression pattern: PPARg1 is
abundantly expressed in adipose tissue, large intestine, and
hematopoietic cells, and to a lower degree in kidney, liver,
muscles, pancreas, and small intestine. PPARg2 is restricted to
white and brown adipose tissue under physiological conditions
[25,33,34].
Endogenous ligands for PPARg include fatty acids and
prostanoids [19,35] that act as weak agonists compared to the
strong synthetic thiazolidinedione agonists [36,37]. The question
of whether PPARg has some highly speciﬁc endogenous ligands or
whether it operates as a rather promiscuous physiological lipid
sensor activated in concert by a variety of fatty acids and
eicosanoids is still not clearly resolved [38–43].
In the human body, PPARg is the master regulator of adipocyte
differentiation, plays an important role in lipid metabolism and
glucose homeostasis, modulates metabolism and inﬂammation in
immune cells, as well as controls cell proliferation [44–46]. PPARg
is induced during the differentiation of preadipocytes into
adipocytes [47–49]. The fact that PPARg null mice are completely
lacking adipose tissue clearly demonstrates that PPARg is essential
for adipocyte differentiation [50]. Furthermore, PPARg directly
activates many genes involved in adipocyte lipid storage [51,52].
Adipose tissue is also the primary tissue responsible for the
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ligands. PPARg controls the expression of numerous factors
secreted from adipose tissue that inﬂuence insulin sensitivity
positively (e.g. adiponectin, leptin) or negatively (e.g. resistin,
tumor necrosis factor-a). In addition, PPARg can directly modulate
the expression of genes involved in glucose homeostasis, e.g. it
upregulates glucose transporter type 4 (Glut4) and c-Cbl-
associated protein (CAP) expression [53,54]. PPARg is also
expressed in various immune system-related cell types, particu-
larly in antigen-presenting cells such as macrophages and
dendritic cells. In these cells, PPARg does not only regulate genes
related to lipid metabolism, but also immunity and inﬂammation
related genes [55–58]. Also the anti-atherosclerosis activity of
PPARg activating thiazolidinediones observed in animal models is
thought to be generated primarily through modulation of PPARg-
regulated gene expression in macrophages [44,59]. In addition to
its metabolic and anti-inﬂammatory properties, PPARg also
modulates proliferation and apoptosis of many cancer cell types,
and is expressed in many human tumors including lung, breast,
colon, prostate, and bladder cancer. As natural and synthetic
PPARg activators have been found to inhibit cancer cell growth in
vitro and in animal models, PPARg might also be a target for new
cancer therapies [44,60,61].
Aside from the availability of agonists and cofactors, the
transcriptional activity of PPARg is also regulated by its
phosphorylation status, providing additional possibilities for
ﬁne-tuning [62,63]. Phosphorylation of PPARg at Ser273 by
cyclin-dependent kinase 5 (Cdk5) was recently linked to obesity,
and anti-diabetic PPARg ligands (e.g. the thiazolidinedione
rosiglitazone) were shown to inhibit the Cdk5-mediated phos-
phorylation of PPARg in adipose tissue [62]. Moreover, several
PPARg ligands with poor agonistic activity but potent anti-diabetic
effects in vivo revealed to be strong inhibitors of the PPARg
phosphorylation by Cdk5. The ligand’s ability to suppress Ser273
phosphorylation correlated well with their anti-diabetic effective-
ness but was independent of classical agonistic effects implied in
some of the side-effects of PPARg ligands currently used in clinics.
Consequently, targeted inhibition of PPARg Ser273 phosphoryla-
tion was suggested as a promising approach for development of a
new generation of anti-diabetic agents [62].
While the application of PPARg agonists is studied in many
different disease conditions, the only approved use for PPARg
ligands so far is the application of thiazolidinediones (full PPARg
agonists) in type 2 diabetes. Thiazolidinediones ﬁrst emerged as
new class of drugs alleviating insulin resistance in patients with
type 2 diabetes in the late 1990s [64–66]. The ﬁrst approved drug
of this class was troglitazone (CS-045), which became ﬁrst
available in March 1997 and was withdrawn from the US market
in March 2000 [67]. Troglitazone activates preferentially PPARg
but is also a ligand of PPARa. As a drug counteracting type 2
diabetes, troglitazone increases insulin sensitivity and glucose
tolerance in obese subjects [68–75]. It was also demonstrated to
inhibit the progression of early atherosclerotic lesions, to lower
blood pressure, as well as to have favorable impact on other known
cardiovascular risk factors [76–78]. In spite of its beneﬁts in
cardiovascular disease, troglitazone was removed from the market
because it induced severe to fatal hepatotoxicity that outweighed
its beneﬁts for patients with diabetes [79–85].
Rosiglitazone (BRL-49653) and pioglitazone are both thiazoli-
dinediones still in clinical use in many countries for glycemic
control in the treatment of type 2 diabetes, although rosiglitazone-
containing anti-diabetes medicines were taken off the market in
the European Union following a European Medicines Agency
(EMA) recommendation for suspension of the marketing author-
izations (press release 23rd of September 2010: EMA/585784/
2010). In the United States the use of rosiglitazone was restrictedby the Food and Drug Administration (FDA) in September 2010 and
in November 2013 the restrictions were removed again, although
according to the ofﬁcially released FDA Drug Safety Communica-
tion (from 25th of November 2013) ‘‘some scientiﬁc uncertainty
about the cardiovascular safety of rosiglitazone medicines still
remains’’. Rosiglitazone has proven its effectiveness in reducing
insulin resistance [86–90]. However, some meta-analyses indicat-
ed that among patients with impaired glucose tolerance or type 2
diabetes the use of rosiglitazone for at least 12 months was
associated with a signiﬁcantly increased risk of myocardial
infarction and heart failure, as well as with an elevated risk of
cardiovascular mortality [91–95]. Furthermore, some case reports
rose concerns that the application of rosiglitazone might be
associated with hepatocellular injury [96] and hepatic failure [97],
side effects similar to those observed for troglitazone. Similar to
rosiglitazone, treatment of type 2 diabetes patients with piogli-
tazone reduces insulin resistance signiﬁcantly [98]. Compared to
rosiglitazone, pioglitazone exerts beneﬁcial effects on the plasma
lipid proﬁle, leading to a lower risk of acute myocardial infarction,
stroke, or heart failure [99–103]. However, the clinical use of
pioglitazone is also limited by the occurrence of several adverse
events, including body-weight gain, ﬂuid retention, and possibly
bladder cancer [104–106].
3. PPARg activation by natural products
The severe adverse effects of thiazolidinediones which led to
their withdrawal from the market or restricted clinical application
are suggested to be a result of full PPARg activation, contrasting the
weak agonistic effect of endogenous PPARg ligands such as fatty
acids and prostanoids [19,107]. Therefore, great research efforts
have recently been undertaken to explore the potential of selective
PPARg modulators (SPPARMs), compounds that improve glucose
homeostasis but elicit reduced side effects due to partial PPARg
agonism based on selective receptor-cofactor interactions and
target gene regulation [107–109]. An illustrative example for a
recently identiﬁed SPPARM is N-acetylfarnesylcysteine, a com-
pound with in vitro and in vivo effectiveness as both a full and
partial agonist depending on the investigated PPARg target gene
[110]. A further research direction under consideration is to
explore the therapeutic potential of dual- and pan-PPAR agonists
activating simultaneously two or all three PPAR receptors,
respectively [111–114].
Medicinal plants have been used to treat various diseases for
thousands of years, and since the 19th century many bioactive pure
compounds isolated from these plants became very successful
drugs [115]. Moreover, still today natural products are an
important source for the discovery and development of new
drugs [116]. Natural products possess a high chemical scaffold
diversity and are evolutionary optimized to serve different
biological functions, conferring them a high drug-likeness and
making them an excellent source for identiﬁcation of new drug
leads [117–119]. The traditional use of plant preparations can
often give strong hints for the pharmacological effects of their
ingredients. A study examining 119 clinically used plant-derived
drugs found that 74% of them were indeed used for disease
indications related to the traditional use of the medicinal plants
from which the substances were isolated [120]. Not surprisingly,
signiﬁcant research efforts were undertaken to explore the PPARg
activating potential of a wide range of natural products originating
from medicinal plants. Summarized in Table 1 are some of the most
interesting examples of investigated sources, their use in
traditional medicine, and the identiﬁed PPARg-activating consti-
tuents. Noteworthy, along with plants and mushrooms applied in
traditional medicines, PPARg-ligands were often identiﬁed in
plants that are common food sources, including the tea plant
Table 1
Species investigated as a source of PPARg ligands, their traditional use, and identiﬁed activating natural products.
Species name Traditional use Identiﬁed PPARg activating natural products
Amorpha fruticosa L. (Fabaceae) Traditionally used to treat hypertension, hematomas,
and contusions in China, Japan, and Korea [201]
Amorfrutins (in the fruits) [187]
Astragalus membranaceus Moench (Fabaceae) In TCM used to reinforce qi and strengthen the
superﬁcial resistance, and promote the discharge of pus
and the growth of new tissue [202]
Formononetin (in ethanolic extracts) [138]
Bixa orellana L. (Bixaceae) In traditional medicine of India different parts of the plant
are used as diuretic, laxative, antibilious, antiemetic and
astringent agents, as blood puriﬁer, in jaundice, in
dysentery, and externally as scar-preventive [203]
Bixin and norbixin (in annatto extracts) [204]
Camellia sinensis (L.) Kuntze (Theaceae) Used worldwide for the preparation of tea; used in the
traditional medicine of India as stimulant, diuretic, and
astringent. In China it is used in the treatment of
diarrhea and dysentery [203]
()-Catechin (in green tea) [205]
Cannabis sativa L. (Cannabaceae) In traditional medicine of India used as hallucinogenic,
hypnotic, sedative, analgesic, and anti-inﬂammatory
agent [203]
D9-Tetrahydrocannabinol [170]
Chromolaena odorata (L.) R.M. King &
H. Rob. (Asteraceae)
In traditional medicine of Thailand used for the treatment
of wounds, rashes, diabetes, and as insect repellent [206]
(9S,13R)-12-Oxo-phytodienoic acid (in
chloroform-soluble extract from the whole plant)
[207] and odoratin (in DCM extract) [208]
Coix lacryma-jobi var. ma-yuen (Rom. Caill.)
Stapf ex Hook. f. (Poaceae)
In TCM used to invigorate the spleen function and
promote urination, alleviate arthritis, arrest diarrhea,
remove heat and facilitate the drainage of pus [202]
Hydroxy unsaturated fatty acids (in acetone extract
from the seeds) [209]
Commiphora mukul (Hook. ex Stocks)
Engl. (Burseraceae)
The oleo-gum-resin is used in traditional medicine of
India for reducing obesity, as well as in the treatment of
rheumatoid arthritis, osteoarthritis and sciatica [203]
Commipheric acid (in guggulipid, the ethyl acetate
extract of the gum of the tree) [210]
Cornus alternifolia L.f. (Cornaceae) Used in TCM as tonic, analgesic, and diuretic [211,212] Kaempferol-3-O-b-glucopyranoside (in 90%
methanol extract from dried leaves) [211]
Cymbopogon citratus (DC.) Stapf (Poaceae) In traditional medicine of India the leaves are used as
stimulant, sudoriﬁc, antiperiodic, and anticatarrhal; the
essential oil is used as carminative, depressant, analgesic,
antipyretic, antibacterial, and antifungal agent [203]
Citral (in lemongrass oil) [213]
Echinacea purpurea (L.) Moench (Asteraceae) Used in indigenous medicine of the native American
Indians: external application for wounds, burns, and
insect bites, chewing of roots for toothache and throat
infections; internal application for pain, cough, stomach
cramps and snake bites [214]
Alkamides (in n-hexane extract of the ﬂowers)
[215]
Elaeis guineensis Jacq. (Arecaceae) In traditional African medicine different parts of the plant
are used as laxative and diuretic, as a poison antidote, as a
cure for gonorrhea, menorrhagia, and bronchitis, to treat
headaches and rheumatism, to promote healing of fresh
wounds and treat skin infections [216]
Tocotrienols (in palm oil) [217]
Elephantopus scaber L. (Asteraceae) Different parts of the plant are used in traditional
medicine of India as astringent agent, cardiac tonic,
diuretic, to treat ulcers and eczema, in rheumatism, to
reduce fever, and to eliminate bladder stones [203]
Deoxyelephantopin [218]
Epimedium elatum C. Morren &
Decne. (Berberidaceae)
Used in TCM to reinforce the kidney yang, strengthen the
tendons and bones, and relieve rheumatic conditions [202]
Acylated ﬂavonol glycosides (in ethanol extract
from the whole plant) [219]
Euonymus alatus (Thunb.)
Siebold (Celastraceae)
Used in TCM to promote blood stasis to promote
menstruation, remove toxic materials, subside swelling,
and kill insects or parasites [202]
Kaempferol and quercetin [134]
Glycine max (L.) Merr. (Fabaceae) The edible beans of the plant are used worldwide as a
food and plant-based protein source [203]
Genistein (in soya beans) [135]
Glycyrrhiza glabra L. (Fabaceae) Used in TCM to reinforce the function of the spleen and
replenish qi, remove heat and counteract toxicity, dispel
phlegm and relieve cough, alleviate spasmodic pain, and
moderate drug actions [202]
50-Formylglabridin, (2R,3R)-3,40 ,7-trihydroxy-30-
prenylﬂavane, echinatin, (3R)-20 ,30 ,7-trihydroxy-
40- methoxyisoﬂavan, kanzonol X, kanzonol W,
shinpterocarpin, licoﬂavanone A, glabrol,
shinﬂavanone, gancaonin L, glabrone (in ethanol
extract from the roots) [220]
Glycyrrhiza foetida Desf. (Fabaceae) Used in the treatment of stomach and throat problems in
traditional medicine of the Marrakech region in Morocco
[221]
Amorfrutins (in the edible roots) [187]
Glycyrrhiza inﬂata Batalin (Fabaceae) Used in TCM to reinforce the function of the spleen and
replenish qi, remove heat and counteract toxicity, dispel
phlegm and relieve cough, alleviate spasmodic pain, and
moderate drug actions [202]
Licochalcone E (in roots) [222]
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Glycyrrhiza uralensis Fisch. ex DC. (Fabaceae) Used in TCM to reinforce the function of the spleen and
replenish qi, remove heat and counteract toxicity, dispel
phlegm and relieve cough, alleviate spasmodic pain, and
moderate drug actions [202]
Flavonoids and 3-arylcoumarins (in ethanolic
extract of the roots) [136]
Limnocitrus littoralis (Miq.) Swingle (Rutaceae) In traditional Vietnamese medicine different parts of the
plant have been used as an expectorant, antitussive product,
for exudation, and the treatment of colds and fevers [223]
Meranzin (in ethyl alcohol/water (90/10, v/v)
extract from the leaves) [224]
Lycium chinense Mill. (Solanaceae) Used in TCM for the treatment of night-sweats,
pneumonia, cough, hematemesis, inﬂammation, and
diabetes mellitus [225]
Fatty acids (in root bark DCM extract) [128]
Magnolia ofﬁcinalis Rehder &
E.H. Wilson (Magnoliaceae)
Used in TCM to eliminate damp and phlegm, and relieve
distension [202]
Magnolol [140,193,194] and honokiol [175,190–
192]
Melampyrum pratense L. (Orobanchaceae) Used in traditional Austrian medicine for the treatment
of gout and rheumatism [122,129]
Lunularin and fatty acids (in aerial parts DCM and
MeOH extracts) [129]
Momordica charantia L. (Cucurbitaceae) In traditional medicine of India different parts of the
plant are used to relieve diabetes, as stomachic, laxative,
antibilious, emetic, and anthelmintic agent. Also used
for the treatment of cough, respiratory diseases, skin
diseases, wounds, ulcer, gout, and rheumatism [203]
Cucurbitane-type triterpene glycosides [226]
Notopterygium incisum C.T. Ting ex
H.T. Chang (Apiaceae)
Used in TCM for the treatment of rheumatism, cold, and
headache [227]
Polyacetylenes (in roots and rhizomes DCM
extract) [228]
Origanum vulgare L. (Lamiaceae) Used as a culinary herb worldwide; used in the
traditional medicine of India as emmenagogue,
antispasmodic, carminative, and expectorant [203]
Biochanin A (in dried leaves) [137]
Panax ginseng C.A. Mey. (Araliaceae) Used in TCM to reinforce the vital energy, to remedy
collapse and restore the normal pulse, beneﬁt the spleen
and lung, promote the production of body ﬂuids, and
anchor the mind [202]
Ginsenoside 20(S)-protopanaxatriol [229] and
ginsenoside Rb1 (in ginseng roots) [230]
Pinellia ternata (Thunb.) Ten. ex
Breitenb. (Araceae)
Used in TCM to remove damp and phlegm, relieve
nausea and vomiting, and eliminate stufﬁness in the
chest and epigastrium [202]
Fatty acids (in different apolar extracts from the
rhizomes) [130]
Pistacia lentiscus L. (var. Chia) (Anacardiaceae) Uses of the resin in traditional medicine of India: as
carminative, diuretic, stimulant, and astringent [203]
Oleanonic acid (in Chios mastic gum) [131]
Pseudolarix amabilis (J. Nelson) Rehder (published
as Pseudolarix kaempferi Gordon) (Pinaceae)
Used in TCM as dermatologic antifungal remedy [231] Pseudolaric acid B (in extracts of the root and trunk
barks) [232]
Pueraria thomsonii Benth. (Fabaceae) Used in TCM for the treatment of fever, acute dysentery,
diarrhea, diabetes, and cardiovascular diseases [233]
Daidzein (in ethanolic extracts) [138]
Robinia pseudoacacia var.
umbraculifer DC. (Fabaceae)
In traditional medicine of India different parts of Robinia
pseudoacacia are used as laxative, antispasmodic, and
diuretic [203]
Amorphastilbol (in seed extract) [234]
Rosmarinus ofﬁcinalis L. (Lamiaceae) Used as a culinary herb worldwide; in traditional
medicine of India essential oil from ﬂowers and leaves is
used as anti-inﬂammatory agent, astringent, antiseptic,
stomachic, carminative, and externally in circulatory
disorders; ﬂowering tops and leaves are used as
carminative and diuretic [203]
Carnosic acid and carnosol (in ethanolic extract of
rosemary) [235]
Salvia ofﬁcinalis L. (Lamiaceae) Used as a culinary herb worldwide; in traditional
medicine of India different parts of the plant are used as
astringent, anti-inﬂammatory, carminative,
antispasmodic, antiseptic, hypoglycaemic, anti-
asthmatic, cholagogue, emmenagogue,
antisudoriferous, diaphoretic, and antipyretic agent, as
well as for the treatment of sore throat, laryngitis,
tonsillitis, and stomatitis [203]
Carnosic acid and carnosol (in ethanolic extract of
sage) [235]; as well as 12-O-methyl carnosic acid
and a-linolenic acid (in DCM extract of sage) [132]
Sambucus nigra L. (Adoxaceae) In traditional medicine of India different parts of the plant
are used as anti-inﬂammatory, anti-catarrhal, diuretic,
and emetic agent, as well as for the treatment of common
cold, inﬂuenza, nasal catarrh, and sinusitis [203]
a-Linolenic acid, linoleic acid, and naringenin (in
MeOH extract of elderﬂowers) [133]
Saururus chinensis (Lour.) Baill. (Saururaceae) In traditional Korean medicine aerial parts of the plant
are used for the treatment of edema, jaundice,
gonorrhea, and several inﬂammatory diseases [236]
Saurufuran A (in roots) [237]
Silybum marianum (L.) Gaertn. (Asteraceae) Widely used worldwide as a supportive agent in the
treatment of a variety of liver diseases; used in TCM to
clear heat and relieve toxic material, to soothe the liver
and to promote bile ﬂow [202]
Isosilybin A (in silymarin, a phenolic mixture from
the fruits of the plant) [238]
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Table 1 (Continued )
Species name Traditional use Identiﬁed PPARg activating natural products
Terminalia bellerica Roxb. (Combretaceae) The fruits are used in traditional medicine of India to
treat anemia, asthma, cancer, diarrhea, hypertension,
inﬂammation, and rheumatism [239]
Gallotannins (in the fruits) [240]
Thymus vulgaris L. (Lamiaceae) Used as a culinary herb worldwide; used in traditional
medicine of India as antiseptic, antibacterial, antifungal,
antiviral, antispasmodic, mild sedative, and
expectorant, for coughs and common cold [203]
Carvacrol (in thyme oil) [241]
Trifolium pratense L. (Fabaceae) Used in traditional medicine of India as deobstruent,
antispasmodic, expectorant, sedative, anti-
inﬂammatory, and anti-dermatosis agent [203]
Isoﬂavones (in red clover extracts) [121]
Vitis vinifera L. (Vitaceae) Widely used worldwide as food (grapes) and for
beverage preparation (wine); used in traditional
medicine of India in prescriptions for cough, respiratory
tract catarrh, subacute cases of enlarged liver and
spleen, as well as in alcohol-based tonics (Aasavs) [203]
Ellagic acid, epicatechin gallate, ﬂavonoids (in
grapes and wine) [242]
Wolﬁporia extensa (Peck) Ginns (published as
Poria cocos F.A. Wolf) (Polyporaceae)
In TCM this mushroom is used to cause urination,
invigorate the spleen function, and calm the
mind [202]
Dehydrotrametenolic acid (in dried sclerotia) [243]
Zingiber ofﬁcinale Roscoe (Zingiberaceae) Widely used as a spice worldwide; in TCM fresh
rhizomes are used to dispel pathogenic factors from
exterior and eliminate cold, arrest vomiting by
warming the middle-energizer, remove phlegm and
arrest cough; dried rhizomes are used to dispel cold
from the spleen and the stomach, promote recovery
from collapse, and warm the lung to expel retained
morbid ﬂuids [202]
6-Shogaol (in ginger roots) [244]
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guineensis), ginger (Zingiber ofﬁcinale), grapes and wine (Vitis
vinifera), and a number of culinary herbs and spices (e.g. Origanum
vulgare, Rosmarinus ofﬁcinalis, Salvia ofﬁcinalis, Thymus vulgaris)
(Table 1). The presence of PPARg ligands in food products warrants
an exploration whether this nuclear receptor may be effectively
activated by the intake of nutraceuticals (by consumption of
functional foods or by dietary supplements). Although most of the
agonists identiﬁed in food sources are weak PPARg agonists per se,
the effects of their metabolites deserve further research to better
estimate their preventive potential. While research in this
direction is largely missing, a previous study reported that some
main metabolites of ﬂavonoid constituents from red clover
(Trifolium pratense) have an up to 100-fold higher PPARg binding
afﬁnity than their precursors [121].
Although in some occasions the traditional use of the species
presented in Table 1 might give hints for bioactivities linked to
PPARg activation, it is important to underline that the applications
of traditional preparations often cover a broad range of symptoms
that are unlikely to be related to PPARg action (e.g. Echinacea
purpurea is traditionally used for the treatment of wounds, burns,
insect bites, toothache, throat infections, pain, cough, stomach
cramps and snake bites; in this example the range of traditional
uses is very likely linked to diverse bioactivities resulting from the
interaction with different molecular targets).
While even many more plant extracts are reported to activate
PPARg [122–127], Table 1 mainly summarizes studies that
identiﬁed bioactive compounds present in the respective extracts.
One reason for frequently omitting the identiﬁcation of bioactive
compounds might be the very high number of medicinal plant
extracts inducing PPARg activation in general. For example, a
recent study examining the PPARg transactivation potential of
extracts from traditional Austrian medicinal plants identiﬁed that
40 out of 71 studied herbal drugs (56% hit rate) are able to induce
PPARg activation when tested at a concentration of 10 mg/mL[122]. This high number of active extracts makes it difﬁcult to
identify the bioactive compounds in each of them. In addition, the
laborious phytochemical analysis is often not rewarded with the
identiﬁcation of interesting novel PPARg ligands but with the re-
isolation of some ubiquitous plant constituents activating the
receptor such as fatty acids [128–133] or ﬂavonoids [121,133–
138].
Besides testing of extracts and bio-guided approaches, virtual
screening emerged as an effective strategy for the discovery of
novel PPARg ligands from natural sources. Rupp et al. used
descriptor-based Gaussian process regression to search for PPARg
agonists based on a data set of 144 published PPARg ligands [139].
A combination of prediction models and manual inspection of the
hit list yielded 15 compounds, which were experimentally
evaluated against PPARa and PPARg activation. Eight compounds
exhibited agonistic activity towards either of these receptors or
both. The most active compound, a truxillic acid derivative, was a
selective PPARg agonist with an EC50 of 10 mM. Petersen et al.
performed a pharmacophore-based virtual screening of a data-
base containing over 57,000 traditional Chinese medicine
constituents [131]. The ligand-based pharmacophore model
consisted of one hydrogen bond acceptor and three hydrophobic
features and was based on a set of 13 selective, partial PPARg
agonists. The virtual hit list contained 939 entries. Exemplarily,
one virtual hit, present in Pistacia lentiscus, was experimentally
investigated involving the testing of the Pistacia oleoresin extract
and the bio-guided fractionation of the active extract. These
efforts led to the discovery of oleanonic acid as a modestly active
partial PPARg agonist. Fakhrudin et al. discovered dieugenol,
magnolol, and tetrahydrodieugenol as partial PPARg agonists
[140]. They used a structure-based pharmacophore model to
screen natural compound databases. Among the highly ranked
hits, several neolignans were isolated or synthesized and
experimentally tested for their in vitro activity against PPARg.
Dieugenol, tetrahydrodieugenol, and magnolol with EC50 values
L. Wang et al. / Biochemical Pharmacology 92 (2014) 73–89 79in the low micromolar or submicromolar range also induced
adipocyte differentiation in 3T3-L1 adipocytes. Lewis et al. used
docking to select natural products for evaluation against PPARg
and in a mouse model for irritable bowel disease [141]. The top-
ranked virtual hit from the docking, a-eleostearic acid, showed
activity in the PPARg binding assay, the cell-based reporter assay,
and the in vivo mouse model for irritable bowel syndrome. Salam
et al. screened a small in-house natural product library using a
multi-step docking protocol [142]. They selected 29 hits from the
200 docked compounds for experimental analysis in a functional
PPARg activity assay. Six compounds, psi-baptigenin, hesperidin,
apigenin, chrysin, biochanin A, and genistein, showed EC50s in the
low micromolar range. Finally, Tanrikulu et al. used a structure-
based pharmacophore model based on the common interactions
of four PPARg X-ray crystal structures in complex with different
agonists [143]. They screened the Analyticon database, which
contains natural products and their semi-synthetic derivatives.
Their efforts led to the discovery of two a-santonin derivatives as
PPARg activators, while a-santonin itself was not active on the
receptor. In summary, several 2D and 3D virtual screening
approaches have successfully discovered structurally diverse
natural product PPARg activators, thereby indicating natural
products as a rich source for novel PPARg agonists.
A selection of natural products well characterized as PPARg
ligands is presented in Table 2. The PPARg-agonistic effects of
endogenous (e.g. fatty acids, prostanoids) [19,26,144–151] and
synthetic [13,151–153] ligands of the receptor have been
reviewed in numerous previous articles and therefore will not
be discussed here. Natural products reported to activate or bind
PPARg with EC50 or respectively IC50 above 50 mM were
considered as less relevant and were therefore omitted from
Table 2. While numerous natural products were so far shown to
interfere with PPARg activity or expression (Table 1 and
references [142,154–173]), the compounds depicted in Table 2
did not only show effectiveness in a cell model responsive to
PPARg activation (e.g. activation of PPARg-dependent reporter
gene expression), but also to directly bind to the receptor in an in
vitro binding assay using puriﬁed PPARg protein. While a binding
assay with a puriﬁed receptor is one of the most direct approaches
to conﬁrm the potential of a compound to physically interact with
PPARg, application of a protein-based in vitro assay alone is not
sufﬁcient to assure that the respective compound can act also in
intact cells (since the compound might not be able to reach PPARg
that is located inside the cell nucleus, due to various reasons such
as inability to penetrate cellular membranes, extrusion from the
cells mediated by membrane efﬂux transporters, metabolic
transformation to products that do not bind PPARg etc.). On
the other side, the use of cellular models alone does not ensure
that the studied compound is a direct receptor ligand, since PPARg
activation as observed in a luciferase reporter model might also be
caused by indirect effects (e.g. increase in PPARg protein
expression, activation of the PPARg dimer partner RXR). The 20
natural products covered in Table 2 include representatives of
seven structural classes (ﬂavonoids, neolignans, stilbenes, amor-
frutins, polyacetylenes, sesquiterpene lactones, and diterpene-
quinone derivatives). This structural variety is consistent with the
known ability of the PPARg ligand-binding domain (LBD) to
accommodate a diversity of chemical scaffolds due to the large
size of the binding site cavity and its adaptability through the
ﬂexibility of side chains [43,174]. With the exceptions of 6-
hydroxydaidzein and ()-catechin, all of the compounds
reviewed in Table 2 revealed to be SPPARMs displaying partial
agonistic effects towards PPARg-dependent reporter gene ex-
pression. Genistein, biochanin A, sargaquinoic acid, sargahydro-
quinoic acid, resveratrol, and amorphastilbol were shown to be
dual agonists able to activate also PPARa along with PPARg(Table 2). Genistein also exerts estrogenic activity at low
concentrations, leading to a concentration-dependent preferen-
tial activation of PPARg or estrogen receptor, translating into
opposite effects on osteogenesis and adipogenesis [135]. Six of the
natural products, i.e. honokiol [175], magnolol [176], resveratrol
[177–186], amorfrutin 1 [187], amorfrutin B [188], and amor-
phastilbol [189], have been demonstrated to improve blood
glucose levels and other relevant parameters in animal models of
diabetes, on some occasions with reduced side effects in
comparison to full thiazolidinedione PPARg ligands (Table 2).
In particular honokiol, amorfrutin 1, amorfrutin B, and amor-
phastilbol reduced weight gain in diabetic animal models.
Furthermore, some of these compounds did not display adverse
liver effects such as hepatomegaly (amorphastilbol) and hepato-
toxicity (amorfrutin 1, amorfrutin B), and amorfrutin B also lacked
adverse effects associated with osteoblastogenesis and ﬂuid
retention (Table 2). Among the studied natural products,
amorfrutin 1 is the only one that was investigated so far for
interference with PPARg Ser273 phosphorylation and was found
to suppress phosphorylation at this residue in the visceral white
adipose tissue of diet-induced obesity (DIO) mice [187]. An
interesting distinct mode of agonism is exerted by the neolignans
honokiol and magnolol, which are dual agonists of PPARg and its
dimer activation partner RXR [140,175,190–194].
Structural details for the binding to PPARg LBD are revealed by
receptor-ligand crystal structures solved for several natural
products (Table 2 and Fig. 2). The PPARg protein comprises an
N-terminal regulatory domain, a central DNA-binding domain,
and a C-terminal LBD (amino acids 204-477) [43,195]. The LBD
consists of 13 a-helices and a small four-stranded b-sheet [196].
Helix H12 of the ligand-dependent activation domain (activation
function-2, AF-2) is essential for ligand binding and PPAR
function. H12 and the loop between H20 and H3 are the most
mobile parts of the LBD. Ligand binding leads to a more rigid
conformation of the LBD, which causes recruitment of coactiva-
tors and consequently transcription of target genes [197]. The
PPARg LBD is a large Y-shaped cavity that is composed of an
entrance domain and two pockets, arm I and arm II (Fig. 2A) [198].
The large size and the ﬂexibility of the binding pocket allow PPARg
to interact with structurally distinct ligands. No ligand is known
that completely ﬁlls this large cavity [43]. However, it enables in
some instances the simultaneous binding of two or even three
molecules, which interact with the binding pocket as well as with
each other, resulting in a more stable binding conformation [199].
Moreover, different ligands bind different areas in the PPARg LBD,
representing different binding modes. Depicted in Fig. 2 are the
binding modes of a selection of ligands co-crystallized with the
PPARg LBD: the full thiazolidinedione agonist rosiglitazone
(protein data bank (PDB) [200] entry PDB: 4ema [199], Fig. 2B);
(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid (9-(S)-
HODE) as a representative endogenous ligand that binds as a
homodimer (PDB: 2vsr [43], Fig. 2C); the natural product
amorfrutin B (PDB: 4a4w [197], Fig. 2D); the neolignan magnolol
that binds as a homodimer (PDB: 3r5n [193], Fig. 2E); and the
ﬂavonoid luteolin binding concomitantly with myristic acid (PDB:
3sz1 [195], Fig. 2F).
In general, strong PPARg agonists such as thiazolidinediones
are known to bind to H12, whereas partial agonists stabilize the b-
sheet and the H20/H3 area. The full agonist rosiglitazone stabilizes
H12 by building hydrogen bonds with Tyr473, which leads to
coactivator recruitment [199]. Whereas just one molecule of the
thiazolidinedione agonists such as rosiglitazone is binding to the
LBD (PDB: 4ema [199], Fig. 2B), some endogenous ligands such as
9-(S)-HODE were demonstrated to activate the receptor as
homodimers (PDB: 2vsr [43], Fig. 2C). The ﬁrst 9-(S)-HODE
molecule binds with its carboxy group via hydrogen bond to Tyr
Table 2









Binds to puriﬁed human PPARg with IC50 = 3.9 [127] or 7.2 mM [137], activates
chimeric Gal4-PPARg-dependent reporter gene expression as partial agonist (with
EC50 = 15.6 mM and maximal efﬁcacy around 3-fold lower than rosiglitazone) [195],
and antagonizes the effect of rosiglitazone (1 mM) upon co-treatment (with
IC50 = 21.8 mM) [195], antagonizes the adipogenesis inducing action of
rosiglitazone (1 mM) in 3T3-L1 cells upon co-treatment (at 5–20 mM) [195],
regulates several PPARg-dependent genes as a weak partial agonist/antagonist, but
acts as a full PPARg agonist on GLUT4 expression in 3T3-L1 cells (at 10–20 mM)
[195], counteracts (at 1–5mM) the IL-8 secretion in human corneal epithelial cells
exposed to hypertonic stress or to the PPARg antagonist GW9662 (at 1 mM) [195],
was co-crystallized with the PPARg LBD whereby luteolin and myristic acid








Binds to recombinant human PPARg (IC50 reported to be 26.0 [134], 5.7 [242], or
2.8 mM [127]), activates PPARg-dependent reporter gene expression as partial
agonist when applied as a single treatment, and antagonizes the effect of
rosiglitazone upon co-treatment (at 1–100 mM) [134], induces the insulin-
dependent glucose uptake but not adipogenesis in 3T3-L1 cells (at 5–50 mM) [134],







Binds to recombinant human PPARg (IC50 = 23.1 [134], 30 [242] or 49.9 mM [245]),
activates PPARg-dependent reporter gene expression as partial agonist when
applied as a single treatment, and antagonizes the effect of rosiglitazone upon co-
treatment (at 1–100 mM) [134], induces the insulin-dependent glucose uptake but
not adipogenesis in 3T3-L1 cells (at 5–50 mM) [134], inhibits rosiglitazone-induced








Binds to puriﬁed PPARg-LBD with IC50 = 9.9 mM [205], activates PPARg-dependent
reporter gene expression as full agonist with EC50 of around 2 mM [205], modulates
expression of PPARg target genes, and promotes adipocyte differentiation of




Binds to puriﬁed PPARg (IC50 = 3.8 mM) and activates chimeric Gal4-PPARg-
dependent reporter gene expression as partial agonist (with EC50 = 3.8 mM and






Binds to puriﬁed human PPARg with IC50 = 19.6 [121] or 23.7 mM [137], activates
chimeric Gal4-PPARg-dependent reporter gene expression as partial agonist (with
EC50 = 39.5 mM and maximal efﬁcacy around 3-fold lower than pioglitazone) [121],
induces adipogenesis in 3T3-L1 cells (at 1-5 mM) [138], activates PPARg promoter
activity in HUVEC transfected with PPRE-reporter plasmids and inhibits monocyte
adhesion to TNF-a activated HUVEC in the presence of ﬂow (at 1 mM) [246],
activates also chimeric Gal4-PPARa-dependent reporter gene expression
[138,247]
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Binds to puriﬁed human PPARg with Ki= 5.7 [135] or 22.5 mM [121], activates
chimeric Gal4-PPARg-dependent reporter gene expression as partial agonist (with
EC50= 18.7 mM and maximal efﬁcacy around 4-fold lower than pioglitazone) [121],
induces adipogenesis in 3T3-L1 cells (at 1-30 mM) [138], activates PPARg promoter
activity in HUVEC transfected with PPRE-reporter plasmids and inhibits monocyte
adhesion to TNF-a activated HUVEC in the presence of ﬂow (at 1 mM; the monocyte
adhesion effect was abolished upon siRNA silencing of PPARg) [246], activates also
the transcriptional activity of PPARa [138,247–249], was shown to act as an
estrogen at low concentrations (1 mM) and as a ligand of PPARg at high
concentrations (>1 mM) leading to concentration-dependent opposite effects on







Binds to puriﬁed human PPARg with IC50 = 3.3 mM [121], activates chimeric Gal4-






6’-Hydroxy- O-desmeth ylangole nsin
Binds to puriﬁed human PPARg with IC50 = 16.7mM [121], activates chimeric Gal4-
PPARg-dependent reporter gene expression as partial agonist with EC50 = 27.7 mM





Dual agonist of PPARg and RXR [175,190–192], binds to puriﬁed human PPARg
(Ki= 22.9 mM) [175], activates PPARg-dependent reporter gene expression as
partial agonist (EC50 = 3.9 mM) [175], induces glucose uptake but not adipogenesis
in 3T3-L1 cells (at 1–10 mM) [175], decreases blood glucose levels in diabetic KKAy




Dual agonist of PPARg and RXRa [140,193,194], binds to puriﬁed human PPARg
(Ki= 2.0 mM) [140], activates PPARg-dependent reporter gene expression as partial
agonist (EC50 = 1.6 mM) [140], induces the recruitment of TRAP220/DRIP-2
coactivator peptide to puriﬁed PPARg (with EC50 of around 0.5 mM and maximal
efﬁcacy around 3-fold lower than pioglitazone) [140], induces adipogenesis
[140,194] and glucose uptake [194] in 3T3-L1 cells (at 10 mM), decreases fasting
blood glucose and plasma insulin levels and prevents or retards diabetic
nephropathy in type 2 diabetic Goto-Kakizaki rats [176], was co-crystallized with






Binds to puriﬁed human PPARg (Ki= 1.37 mM) [250], activates chimeric Gal4-
PPARg-dependent reporter gene expression as partial agonist (at 50–100 mM)
[251], inhibits rosiglitazone-induced PPARg luciferase reporter transactivation
with IC50 = 27.4 mM [250], affects glucose and lipid metabolism as well as
inﬂammation by interference with PPARg in several in vitro and in vivo animal
models [177–185] and improves insulin sensitivity in type 2 diabetic patients
[186], is also a ligand of PPARa [250,252], was co-crystallized with the PPARg-LBD
(PDB: 4jaz) [250]
L. Wang et al. / Biochemical Pharmacology 92 (2014) 73–89 81





Binds to puriﬁed human PPARg (IC50 = 0.85 mM) and activates human PPARg-
dependent luciferase reporter gene expression (EC50 = 5 mM; maximal fold
activation of 83% as compared to the full agonist troglitazone) [234], binds and
activates with a similar potency also PPARa [234], improves glucose and lipid







Binds to puriﬁed PPARg (Ki= 0.24 mM) and activates chimeric Gal4-PPARg-
dependent reporter gene expression as partial agonist (with EC50 = 0.46 mM and
maximal efﬁcacy 61% lower than rosiglitazone) [187], selectively modulates PPARg
gene expression networks in human adipocytes with a different pattern in
comparison to synthetic PPARg agonists [187], improves insulin resistance and
other metabolic and inﬂammatory parameters without concomitant increase of fat
storage or other unwanted side effects such as hepatotoxicity in diet-induced
obese and db/db mice [187], blocks PPARg Ser273 phosphorylation in DIO mice





Binds to puriﬁed PPARg (Ki= 0.29 mM), and activates chimeric Gal4-PPARg-
dependent reporter gene expression as partial agonist (with EC50 = 1.2 mM and
maximal efﬁcacy 70% lower than rosiglitazone) [187], selectively modulates PPARg
gene expression networks in human adipocytes with a different pattern in
comparison to synthetic PPARg agonists [187], was co-crystallized with the





Binds to puriﬁed PPARg (Ki= 0.019 mM) and activates chimeric Gal4-PPARg-
dependent reporter gene expression as partial agonist (with EC50 = 0.073 mM and
maximal efﬁcacy 4-fold lower than rosiglitazone) [188], induces partial
recruitment of several PPARg transcriptional coactivators [188], regulates gene
expression in human adipocytes in a PPARg-dependent manner [188], in insulin-
resistant mice, it shows liver-protecting properties and improves insulin
sensitivity, glucose tolerance, and blood lipid variables, without weight gain or
adverse effects on osteoblastogenesis and ﬂuid retention [188], was co-crystallized




Binds to puriﬁed human PPARg (Ki= 3.1 mM) [228], activates PPARg-dependent
reporter gene expression as partial agonist (at 1–30 mM), and antagonizes the
effect of rosiglitazone upon co-treatment [228], induces adipogenesis and glucose
uptake in 3T3-L1 adipocytes at 10 mM [228]
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Binds to puriﬁed PPARg-LBD (KD= 3.4 mM) but not to PPARa-LBD or PPARb/d-LBD
[218], enhances the transcriptional activity of full-length PPARg and Gal4-PPARg-
LBD chimera as a partial agonist (at 1–20 mM) [218], enhances the transcription







Binds to puriﬁed PPARg (IC50 = 0.255 mM) [253], activates PPARg-dependent
reporter gene expression as a partial agonist (at 1–30 mM) [253], enhances
adipocyte differentiation in 3T3-L1 cells by increasing the expression of genes






Binds to puriﬁed PPARg (IC50 = 0.725 mM) [253], activates PPARg-dependent
reporter gene expression as a partial agonist (at 1–30 mM) [253], enhances
adipocyte differentiation in 3T3-L1 cells by increasing the expression of genes
critical for adipocyte phenotype (at 10 mM) [253], activates also PPARa (at 1–
30 mM) [253]
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ligands. The tail, which is located in an area also occupied by highly
potent agonists, interacts via van der Waals contacts with Phe363
and other amino acids. The second molecule is located between H3
and the b-sheet, an area which is occupied also by synthetic partial
agonists. Its carboxylate group forms a salt bridge with Arg288, an
amino acid, which is not involved in the binding of thiazolidine-
diones [43].
The partial PPARg agonists amorfrutin 1, 2, and B (PDB: 2yfe,
PDB: 4a4 v, and PDB: 4a4w, respectively [187,197]) are localized
and oriented almost identically in the PPARg LBD. They bind to
and therefore stabilize the b-sheet as well as H3 of PPARg by
hydrogen bonds and van der Waals contacts. The reason for the
high afﬁnity of amorfrutins to PPARg is the interaction of the
carboxyl group to Ser342 of the b-sheet via hydrogen bonds. Also
Arg288 of H3 is stabilized by amorfrutins. The replacement of
Arg288 by threonins in PPARa and PPARb/d is likely the reason for
the selective PPARg activity of amorfrutins 1, 2, and B. However,
there are also differences in their interactions with the LBD.
Amorfrutin B shows signiﬁcantly higher afﬁnity than other
reported amorfrutins, similar to that of rosiglitazone. This is
caused by the long geranyl side chain, which forms additional
hydrophobic interactions especially to Arg288 of H3 and to H4/5
[197].According to the PDB: 3sz1, the PPARg partial agonist luteolin
binds to the PPARg LBD simultaneously with the long-chain fatty
acid myristic acid. The two molecules stabilize the b-sheet as well
as the loop among H20 and H3. Luteolin interacts via hydrogen
bonds with Lys265 and His266 at the loop that links H20 and H3
and builds hydrophobic contacts with various amino acids.
Myristic acid occupies H3, H5, and H7 and interacts with
Arg288 (H3) via a salt bridge. Luteolin and the carboxylate of
myristic acid are connected via a water molecule through a
hydrogen bond. This water molecule seems to be important for
keeping luteolin in the LBD [195].
Similar to some endogenous ligands such as 9-(S)-HODE, two
magnolol molecules were demonstrated to cooperatively occupy
the PPARg LBD. One magnolol molecule occupies AF-2, the other
one the b-sheet. In AF-2, the hydroxyl group of magnolol makes a
hydrogen bond with Ser289 in H3 and water-mediated hydrogen
bonds with Tyr473. In the b-sheet, the hydroxyl group of the
second magnolol forms a hydrogen bond with Ser342. Further-
more, there is also a water-mediated hydrogen bond in the b-sheet
to magnolol. The magnolol structure is highly ﬂexible due to the
single bond connecting the two 5-ally-2-hydroxyphenyl moieties.
It exhibits three different conformations when binding to PPARg
and RXRa, which bind two and one molecule of magnolol,
respectively [193].
Fig. 2. Binding modes of selected PPARg ligands co-crystallized with PPARg. (A) The Y-shaped PPARg LBD composed of one entrance domain and two arms (arm I is
substantially polar, arm II is mainly hydrophobic) [174]. Observed protein-ligand interactions are presented between the human PPARg LBD and (B) the synthetic agonist
rosiglitazone (PDB: 4ema), (C) the endogenous agonist 9-(S)-HODE binding as a homodimer (PDB: 2vsr), the natural ligands (D) amorfrutin B (PDB: 4a4w), (E) magnolol
binding as homodimer (PDB: 3r5n), and (F) luteolin binding as a mixed dimer with myristic acid (PDB: 3sz1). The interactions were visualized by means of the software
LigandScout [254] with the following color code: hydrogen bond acceptor (red arrow), hydrogen bond donor (green arrow), hydrophobic interaction (yellow sphere), and
negative ionizable area (red star). The ligand binding pocket is depicted as surface; its colors are based on the lipo- and hydrophilicity. Contacts with active site water
molecules are not shown.
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Natural products prove to be a rich source for the discovery of
novel PPARg ligands and many structurally diverse agonists of
this receptor were recently identiﬁed from traditionally used
medicinal plants or food sources. Interestingly, the majority of
identiﬁed natural compounds are rather weak agonists of PPARg,
often activating the receptor as partial agonists, with activation
pattern distinct from the full thiazolidinedione agonists and more
similar to endogenous ligands with weaker activation potential
such as fatty acids and prostanoids. Noteworthy, several PPARg
agonists were identiﬁed in plants used as culinary spices,
beverages or food sources, opening the possibility to consider
modulation of the activity of this nuclear receptor through dietary
interventions. While most of the identiﬁed natural products only
activate PPARg as SPPARMs, some are dual agonists able to also
activate PPARa (Table 2). An especially interesting activation
pattern is observed for the neolignans magnolol and honokiol,
which are ligands for both PPARg and its dimer activation partner
RXR. The neolignan honokiol and several other natural products
have also demonstrated beneﬁcial metabolic effects in diabetic
animal models, with reduced side effects in comparison to full
thiazolidinedione agonists. Many extracts from medicinal plants
reported in the literature as PPARg activators are so far notthoroughly investigated. The identiﬁcation of their active con-
stituents might provide further interesting ligands in the future.
In conclusion, a range of PPARg activating natural products and
plant extracts were recently described that bear a good potential to
be further explored for therapeutic effectiveness as well as to be
studied as potential dietary supplements to counteract the
metabolic syndrome and type 2 diabetes.
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